Reactions similar to those reported by people without Down syndrome

0.8% of vaccinated people contracted COVID-19 infections after vaccination

Results stratified by age

Age 12 – 17 (n=329) | Age 18 + (n=1379)
--- | ---
0.3% of those 12 – 17 years | 0.9% of those 18+ years
5 cases after 2nd dose | 8 cases after 1st dose
• All recovered | • 2 hospitalized
• All recovered | • 80% of those after 1st dose
• No emergency department or urgent care visit

Reaction did not require medical care:          98.1%
Doctor or clinic visit needed:                             0.9%
Emergency department or urgent care visit:  0.0%
Other:                                                                     0.0%
Don’t know:                                                          1.1%

Reaction did not require medical care:          95.0%
Doctor or clinic visit needed:                             3.9%
Emergency department or urgent care visit:  0.6%
Other:                                                                     0.5%
Don’t know:                                                          0.0%

Very few reactions required clinical care

0.8% of vaccinated people contracted COVID-19 infections after vaccination

0.0% of those 12 – 17 years | 0.0% of those 18+ years
--- | ---
1 case after 2nd dose | 5 cases after 2nd dose
• More than 60 days after 2nd dose | • All after 60 days
• Not admitted to hospital | • None admitted to hospital
• Symptoms for 10 days | • All recovered
• Fully recovered

Limitations

• Participants were from different countries with different health care systems and resources; thus conclusions may not extend to each setting
• The majority of participants were adults (81%)
• The average time between 2nd dose and participation in the survey was 112 days and therefore does not address long-term protection

Acknowledgments

The Trisomy 21 Research Society (T21RS) COVID-19 Taskforce developed the survey, with the financial and dissemination support of Down Syndrome Affiliates in Action (DSAIA), Down Syndrome Medical Interest Group (DSMIG), GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Congress (NDSC), National Down Syndrome Society (NDSS), National Organization for Rare Disorders (NORD), Oxford-AstraZeneca, Pfizer-BioNTech, Pharmaceuticals, and the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). These and other international Down syndrome organizations are members of the T21RS COVID-19 stakeholders advisory group that provided advice to inform the design of the survey questions and interpretation of results, including the Global Down Syndrome Foundation (GDSF), Global Foundation for Rare Diseases (GFRD), Global Organisation for Rare Disorders (GORD), International Down Syndrome Congress (ICDS), Italian National Society of Trisomy 21 (SIT21), Le Jeune Foundation (France), National Organization for Rare Disorders (NORD), Oxford-AstraZeneca, Pfizer-BioNTech, Pharmaceuticals, and the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). The T21RS COVID-19 stakeholders advisory group provided advice to inform the design of the survey questions and interpretation of results, including the Global Down Syndrome Foundation (GDSF), Global Foundation for Rare Diseases (GFRD), Global Organisation for Rare Disorders (GORD), International Down Syndrome Congress (ICDS), Italian National Society of Trisomy 21 (SIT21), Le Jeune Foundation (France), National Organization for Rare Disorders (NORD), Oxford-AstraZeneca, Pfizer-BioNTech, Pharmaceuticals, and the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). This report is not intended to be a survey of all Down syndrome families and clinicians who contributed to the survey.